Message Font: Serif | Sans-Serif
No. of Recommendations: 4
hi fellow Fools,

here are the data of the CRPC trial reported @ ESMO 2012 - already posted on

My take:
1) the study design was a non-randomized expansion of a phase 2 randomized discontinuation study - this means that all patients were already treated with Cabo and had no severe tolerability issues.
2) Encouraging: the dose of 40 mg seems to be as effective as 100 mg once daily.
3) Outstanding effect: 67% (26 of 39 pats.) showed a >=30% decrease in their circulating tumor cells - but why only 39 patients out of the initially 51 enrolled ? I have to dig deeper into the published data to answer this discrepancy.

So far no negative news for Cabo - IMO, nothing that could make EXEL shares plummet ahead of a probable MTC approval (in 2 to 3 weeks ?).

fool on,
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.